mammalian
eye
protect
pathogen
infl
ammat
rel
immuneprivileg
environ
stringent
mechan
activ
regul
extern
injuri
infect
autoimmun
eye
contain
varieti
cell
express
vasoact
neuropeptid
vn
receptor
locat
sclera
cornea
iri
ciliari
bodi
ciliari
process
retina
vn
import
activ
adenyl
cyclas
deriv
cyclic
adenosin
monophosph
camp
adenosin
triphosph
atp
impair
vn
function
would
arguabl
imped
camp
product
imped
util
atp
thu
vn
autoimmun
may
etiolog
factor
retinopathi
involv
perturb
purinerg
signal
sound
blood
suppli
necessari
exist
function
properti
retina
paper
postul
impair
endotheli
barrier
bloodretin
barrier
well
certain
infl
ammatori
respons
may
aris
disrupt
vn
function
phosphodiesteras
inhibitor
purinerg
modul
may
role
treatment
postul
vn
autoimmun
retinopathi
vasoact
intestin
peptid
vip
pituitari
adenyl
cyclaseactiv
polypeptid
pacap
vasoact
neuropeptid
vn
shown
exist
mammalian
eye
area
sclera
cornea
iri
ciliari
bodi
ciliari
process
retina
import
featur
vn
receptor
abil
activ
adenyl
cyclas
ac
produc
cyclic
adenosin
monophosph
camp
adenosin
triphosph
atp
retina
mammal
vn
receptor
class
ii
g
proteincoupl
receptor
gpcr
import
regul
level
atp
camp
addit
atp
vasoact
signal
microvasculatur
rat
retina
camp
regul
neurolog
metabol
infl
uenc
bloodbrain
bbb
bloodretin
brb
barrier
permeabl
coordin
neuroregulatori
pathway
induc
protect
neuron
apoptosi
howev
failur
metabol
atp
adequ
may
result
elev
extracellular
atp
level
set
train
perturb
purinerg
signal
initi
signifi
cant
neuroand
retinotox
pacap
also
act
neurotransmitt
retinohypothalam
tract
mediat
photic
regul
brain
biolog
clock
along
neuropeptid
like
signifi
canc
part
eye
addit
retina
moreov
pacap
protect
effect
monosodium
glutam
msg
induc
retin
degener
kainic
acid
retin
degener
pacap
glutam
costor
retinohypothalam
tract
pacap
attenu
glutamateinduc
neurotox
cultur
retin
neuron
suggest
compromis
vn
would
signifi
cant
detriment
impact
retin
viabil
function
pacap
role
relax
pericyt
may
form
basi
diagnost
procedur
diabet
retinopathi
view
vasodilatori
role
vn
along
hypoxia
protect
may
place
prevent
ischem
retin
degener
vip
pacap
like
import
role
retin
develop
pacap
vip
autoimmun
hypothes
previous
causal
agent
retinopathi
vn
function
postul
autoimmun
emerg
fi
eld
may
relev
clinic
ophthalmologist
opportun
develop
novel
treatment
retin
patholog
may
aris
consequ
autoimmun
exampl
peripher
vitreochorioretin
dystrophi
pvcrd
shown
aris
local
reaction
note
self
antibodi
detect
pvcrd
case
normal
level
immun
complex
blood
antibodyinduc
apoptosi
possibl
mechan
retin
patholog
antibodi
antirecoverin
induc
retinopathi
exert
cytotox
effect
retin
cell
activ
caspas
apoptot
pathway
occur
result
effect
retin
photoreceptor
cell
death
degener
photoreceptor
layer
loss
sight
addit
presenc
antirecoverin
immunoreact
may
possibl
causal
factor
patient
retin
patholog
importantli
virus
coronaviru
exacerb
retin
degener
murin
model
retin
diseas
manifest
retin
vascul
presenc
antiretin
antibodi
acut
infl
ammat
brb
compromis
occur
earli
stage
diseas
mice
autoimmun
reactiv
neurodegener
featur
later
stage
retin
diseas
fi
nding
support
involv
autoimmun
mechan
retin
degener
signifi
cant
contribut
camp
function
brb
suggest
retin
patholog
could
involv
vn
autoimmun
stabil
brb
function
may
associ
nitric
oxid
phosphodiesteras
enzym
pde
camp
regul
failur
metabol
atp
camp
could
result
perturb
purinerg
signal
retina
inde
caus
atp
elev
subsequ
patholog
demonstr
purinerg
activ
may
promot
effect
diabetesinduc
increas
vulner
retin
microvessel
previous
unrecogn
mechan
diabet
retinopathi
progress
certainli
atp
particip
bidirect
signal
glial
cell
retina
gliosi
may
imped
recoveri
repair
retin
detach
present
hypothesi
postul
camp
reli
extens
pacapvip
activ
ac
compromis
function
would
result
impair
camp
deriv
atp
atp
implic
endogen
trigger
microgli
activ
reactiv
gliosi
may
affect
microglia
neuron
oligodendrocyt
microgli
activ
might
exacerb
condit
trauma
hypoxia
impair
metabol
intracellular
atp
may
lead
extravas
atp
extracellular
compart
ectonucleotidas
respons
metabol
extracellular
atp
util
avail
determin
balanc
releas
remov
enzymat
degrad
uptak
mechan
may
result
perturb
purinerg
signal
thu
pathomechan
involv
atp
toxic
may
occur
potenti
seriou
consequ
retinopathi
may
occur
vn
autoimmun
imped
camp
product
elev
atp
level
theoret
phosphodiesteras
inhibitor
pdei
therapi
may
assist
restor
camp
level
howev
atp
toxic
may
remain
issu
purinerg
antagonist
may
act
protect
retin
neurodegener
atp
toxic
importantli
pdei
effect
regul
camp
interestingli
pdei
also
enhanc
tyrosin
hydroxylas
phenotyp
dopaminerg
cell
import
retin
develop
inhibitor
could
consid
candid
therapeut
drug
treat
diseas
associ
disord
retin
circul
without
sever
cardiovascular
sideeffect
although
care
taken
use
inhibitor
nevertheless
case
may
exist
undertak
therapeut
trial
campspecifi
c
pde
inhibitor
retinopathi
result
vn
autoimmun
patholog
subsequ
proven
possibl
associ
vn
autoimmun
retinopathi
human
seem
plausibl
suggest
need
research
specifi
c
therapeut
intervent
may
alreadi
avail
could
develop
prevent
treatment
vn
autoimmun
retinopathi
recent
evid
suggest
vip
may
use
treatment
experiment
autoimmun
uveoretin
eau
possibl
vasoact
neuropeptid
act
therapeut
context
may
support
hypothesi
vn
impair
etiolog
retin
patholog
author
report
confl
ict
interest
work
